Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the.
Search jobs 06-May-2021 Asia-Pacific Lung Cancer Therapeutics Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast to 2027 The reliable
“XYZ” report presents the best market and business solutions to Industry in this rapidly revolutionizing marketplace to thrive in the market. This market research report is a vigilant investigation of the current scenario of the market and future estimations which spans several market dynamics. The market definition gives the scope of a particular product with respect to the driving factors and restraints in the market.
This industry document forecasts the size of the market with information on key vendor revenues, development of the industry by upstream and downstream, industry progress, key companies, along market segment type and market application. Key data and information used while preparing this market report have been collected from consistent
Search jobs 06-May-2021 Middle East and Africa lung cancer therapeutics market is expected to register a healthy CAGR in the forecast period of 2019 to 2026 The reliable
“Middle East and Africa lung cancer therapeutics market” report presents the best market and business solutions to Industry in this rapidly revolutionizing marketplace to thrive in the market. This market research report is a vigilant investigation of the current scenario of the market and future estimations which spans several market dynamics. The market definition gives the scope of a particular product with respect to the driving factors and restraints in the market.
This industry document forecasts the size of the market with information on key vendor revenues, development of the industry by upstream and downstream, industry progress, key companies, along market segment type and market application. Key data and information used while preparing this mar
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
- RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes
- Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during third quarter of 2021
- Expanded potential indications for LP-184 to include ATRT pediatric brain cancers
- Initiated preclinical development of new molecular entity, LP-284, in hematologic cancers
- Strengthened intellectual property portfolio with filing of over 10 patent applications
- Launched research and development collaboration leveraging RADR® for accelerating drug development for Actuate Therapeutics GSK3β drug candidate